Brunstein Claudio G, Cutler Corey S, DeFor Todd E, Kim Haesook, Bejanyan Nelli, Garfall Alfred, Verneris Michael R, Chen Yi-Bin, Warlick Erica D, Spitzer Thomas, Miller Jeffrey S, Antin Joseph H, Weisdorf Daniel J, Soiffer Robert, Wagner John E, Ballen Karen K
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
The Dana Farber Cancer Institute, Boston, Massachusetts.
Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.
We studied the effect of HLA-C matching in 515 patients after double umbilical cord blood (UCB) transplantation. After HLA matching HLA-A, -B, and -DRB1 at the allele level, we scored patients according to number of donor-recipient HLA-C matches at 4 possible loci: 2 from each donor unit, at the allele level. Given a direct interaction between HLA-A, -B, and -DRB1 matching and HLA-C score, we analyzed HLA-C matching in those receiving at least 1 2/6 to 4/6 HLA-matched unit (n = 389) versus those receiving only 5/6 or 6/6-matched units (n = 126). In those with at least 1 2/6 to 4/6 HLA-matched unit, a better HLA-C matching score was associated with significantly lower risk of death of any cause and nonrelapse mortality and better disease-free survival. There was no association with the risk of relapse, acute and chronic graft-versus-host disease, and hematopoietic recovery. In contrast, among patients receiving only allele-level 5/6 or 6/6 HLA-matched UCB units, HLA-C match had no demonstrable effect on any outcome. For patients receiving at least 1 allele-level 2/6 to 4/6 HLA-matched UCB unit, matching at HLA-C reduces nonrelapse mortality and improves survival.
我们研究了515例双份脐血(UCB)移植患者中HLA - C配型的影响。在等位基因水平上对HLA - A、- B和 - DRB1进行HLA配型后,我们根据供受者在4个可能位点的HLA - C匹配数量对患者进行评分:每个供者单位有2个位点,在等位基因水平。考虑到HLA - A、- B和 - DRB1配型与HLA - C评分之间存在直接相互作用,我们分析了接受至少1个2/6至4/6 HLA匹配单位的患者(n = 389)与仅接受5/6或6/6匹配单位的患者(n = 126)的HLA - C配型情况。在接受至少1个2/6至4/6 HLA匹配单位的患者中,更好的HLA - C匹配评分与任何原因导致的死亡风险和非复发死亡率显著降低以及无病生存率提高相关。与复发风险、急性和慢性移植物抗宿主病以及造血恢复无关。相比之下,在仅接受等位基因水平5/6或6/6 HLA匹配脐血单位的患者中,HLA - C配型对任何结局均无明显影响。对于接受至少1个等位基因水平2/6至4/6 HLA匹配脐血单位的患者,HLA - C配型可降低非复发死亡率并提高生存率。